12 Einträge gefunden

1. Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer

   1. Oliveira-Ferrer, L
   2. Heßling, A
   3. Trillsch, F
   4. Mahner, S
   5. Milde-Langosch, K

   2015 - Forschungsinformationssystem des UKE - frei zugänglich
2. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study

   1. Trillsch, F
   2. Mahner, S
   3. Vettorazzi, E
   4. Woelber, L
   5. Reuss, A
   6. Baumann, K
   7. Keyver-Paik, M-D

   2015 - Forschungsinformationssystem des UKE
3. 8p deletion is strongly linked to poor prognosis in breast cancer

   1. Lebok, P
   2. Mittenzwei, A
   3. Kluth, M
   4. Özden, C
   5. Taskin, B
   6. Hussein, Kais
   7. Möller, K

   2015 - Forschungsinformationssystem des UKE
4. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)

   1. Ruscito, I
   2. Dimitrova, D
   3. Vasconcelos, I
   4. Gellhaus, K
   5. Schwachula, T
   6. Bellati, F
   7. Zeillinger, R

   2014 - Forschungsinformationssystem des UKE
5. c-FOS suppresses ovarian cancer progression by changing adhesion

   1. Oliveira Ferrer, Leticia
   2. Rößler, K
   3. Haustein, V
   4. Schröder, Christine
   5. Wicklein, D
   6. Maltseva, D
   7. Khaustova, N

   2014 - Forschungsinformationssystem des UKE
6. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study

   1. Trillsch, F
   2. Mahner, S
   3. Woelber, L
   4. Vettorazzi, E
   5. Reuss, A
   6. Ewald-Riegler, N
   7. de Gregorio, N

   2014 - Forschungsinformationssystem des UKE
7. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

   1. Harter, P
   2. Mahner, S
   3. Hilpert, F
   4. Runnebaum, I
   5. Ortmann, O
   6. Mustea, A
   7. Sehouli, J

   2013 - Forschungsinformationssystem des UKE
8. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013

   1. Wagner, U
   2. Harter, P
   3. Hilpert, F
   4. Mahner, S
   5. Reuß, A
   6. du Bois, A
   7. Petru, E

   2013 - Forschungsinformationssystem des UKE
9. Surgical intervention in relapsed ovarian cancer is beneficial: pro

   1. Harter, P
   2. Heitz, F
   3. Mahner, S
   4. Hilpert, F
   5. du Bois, A

   2013 - Forschungsinformationssystem des UKE
10. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

    1. Mahner, S
    2. zu Eulenburg, Christine
    3. Staehle, A
    4. Wegscheider, K
    5. Reuss, A
    6. Pujade-Lauraine, E
    7. Harter, P

    2013 - Forschungsinformationssystem des UKE
11. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study

    1. Hofstetter, G
    2. Concin, N
    3. Braicu, I
    4. Chekerov, R
    5. Sehouli, J
    6. Cadron, I
    7. Van Gorp, T

    2013 - Forschungsinformationssystem des UKE
12. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study

    1. Braicu, E I
    2. Fotopoulou, C
    3. Van Gorp, T
    4. Richter, R
    5. Chekerov, R
    6. Hall, C
    7. Butz, H

    2013 - Forschungsinformationssystem des UKE